Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 712

1.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P.

Cardiovasc Diabetol. 2019 Jun 4;18(1):71. doi: 10.1186/s12933-019-0864-7. Review.

2.

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.

Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM.

Am Heart J. 2018 Dec;206:80-93. doi: 10.1016/j.ahj.2018.09.011. Epub 2018 Sep 29.

3.
4.

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T; K-877-04 Study Group.

Atherosclerosis. 2016 Jun;249:36-43. doi: 10.1016/j.atherosclerosis.2016.02.029. Epub 2016 Feb 26.

5.

Residual macrovascular risk in 2013: what have we learned?

Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P; Residual Risk Reduction Initiative (R3i).

Cardiovasc Diabetol. 2014 Jan 24;13:26. doi: 10.1186/1475-2840-13-26. Review.

6.
7.

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Hermans MP, Fruchart JC.

Ther Adv Chronic Dis. 2011 Sep;2(5):307-23. doi: 10.1177/2040622311413952.

8.

[The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome].

Millán Núñez-Cortés J, Montoya JP, Salas XP, Hernández Mijares A, Carey VJ, Hermans MP, Sacks FM, Fruchart JC.

Endocrinol Nutr. 2011 Jan;58(1):38-47. doi: 10.1016/j.endonu.2010.10.004. Epub 2011 Jan 3. Spanish.

PMID:
21208833
9.

Combination lipid therapy in type 2 diabetes.

Sacks FM, Carey VJ, Fruchart JC.

N Engl J Med. 2010 Aug 12;363(7):692-4; author reply 694-5. doi: 10.1056/NEJMc1006407. No abstract available.

PMID:
20842772
10.

Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i).

Fruchart JC, Sacks FM, Hermans MP; International Steering Committee of R(3)i.

Curr Med Res Opin. 2010 Aug;26(8):1793-7. doi: 10.1185/03007995.2010.489341.

PMID:
20482323
11.

Apolipoprotein A-V modulates insulin secretion in pancreatic beta-cells through its interaction with midkine.

Helleboid-Chapman A, Nowak M, Helleboid S, Moitrot E, Rommens C, Dehondt H, Héliot L, Drobecq H, Fruchart-Najib J, Fruchart JC.

Cell Physiol Biochem. 2009;24(5-6):451-60. doi: 10.1159/000257484. Epub 2009 Nov 4.

12.

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity.

Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5.

PMID:
19805654
13.

Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease.

Fruchart JC.

Atherosclerosis. 2009 Jul;205(1):1-8. doi: 10.1016/j.atherosclerosis.2009.03.008. Epub 2009 Mar 20. Review.

PMID:
19386311
14.

Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis.

Brunham LR, Singaraja RR, Duong M, Timmins JM, Fievet C, Bissada N, Kang MH, Samra A, Fruchart JC, McManus B, Staels B, Parks JS, Hayden MR.

Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):548-54. doi: 10.1161/ATVBAHA.108.182303. Epub 2009 Feb 5.

PMID:
19201688
15.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.

Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P.

Am J Cardiol. 2008 Nov 17;102(10 Suppl):1K-34K. doi: 10.1016/S0002-9149(08)01833-X. Review.

PMID:
19068318
16.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.

Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P; Residual Risk Reduction Initiative (R3I).

Diab Vasc Dis Res. 2008 Nov;5(4):319-35. doi: 10.3132/dvdr.2008.046. Review.

PMID:
18958843
17.

Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages.

Bultel S, Helin L, Clavey V, Chinetti-Gbaguidi G, Rigamonti E, Colin M, Fruchart JC, Staels B, Lestavel S.

Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2288-95. doi: 10.1161/ATVBAHA.108.175042. Epub 2008 Sep 18.

PMID:
18802017
18.

Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity.

Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, Hum DW, Fruchart JC, Staels B.

Mol Endocrinol. 2008 Nov;22(11):2433-47. doi: 10.1210/me.2008-0092. Epub 2008 Aug 28.

PMID:
18755856
19.

Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.

Mansouri RM, Baugé E, Gervois P, Fruchart-Najib J, Fiévet C, Staels B, Fruchart JC.

Circ Res. 2008 Aug 29;103(5):450-3. doi: 10.1161/CIRCRESAHA.108.179861. Epub 2008 Jul 24.

PMID:
18658049
20.

[PPAR receptors at the crossroads of obesity, diabetes and cardiovascular diseases].

Gilde A, Fruchart JC, Staels B.

Journ Annu Diabetol Hotel Dieu. 2007:21-38. Review. French. No abstract available.

PMID:
18610756
21.

Glucose regulates the expression of the apolipoprotein A5 gene.

Nowak M, Helleboid-Chapman A, Jakel H, Moitrot E, Rommens C, Pennacchio LA, Fruchart-Najib J, Fruchart JC.

J Mol Biol. 2008 Jul 25;380(5):789-98. doi: 10.1016/j.jmb.2008.04.057. Epub 2008 Apr 30.

PMID:
18572192
22.

The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages.

Fontaine C, Rigamonti E, Pourcet B, Duez H, Duhem C, Fruchart JC, Chinetti-Gbaguidi G, Staels B.

Mol Endocrinol. 2008 Aug;22(8):1797-811. doi: 10.1210/me.2007-0439. Epub 2008 May 29.

23.

DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.

Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M, Dubois V, de Coupade C, Boukaissi M, Chéné AS, Tranchant I, Arranz V, Zoubaa I, Fruchart JS, Ravel D, Kearsey J.

Clin Cancer Res. 2008 Apr 1;14(7):2145-53. doi: 10.1158/1078-0432.CCR-07-4580.

24.

Novel peroxisome proliferator activated receptor-alpha agonists.

Fruchart JC.

Am J Cardiol. 2007 Dec 3;100(11 A):n41-6. Review.

PMID:
18047852
25.

FXR-deficiency confers increased susceptibility to torpor.

Cariou B, Bouchaert E, Abdelkarim M, Dumont J, Caron S, Fruchart JC, Burcelin R, Kuipers F, Staels B.

FEBS Lett. 2007 Nov 13;581(27):5191-8. Epub 2007 Oct 12.

26.

In vivo characterization of human APOA5 haplotypes.

Ahituv N, Akiyama J, Chapman-Helleboid A, Fruchart J, Pennacchio LA.

Genomics. 2007 Dec;90(6):674-9. Epub 2007 Oct 23.

27.

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators.

N Engl J Med. 2007 Sep 27;357(13):1301-10.

28.

Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome.

Niculescu LS, Fruchart-Najib J, Fruchart JC, Sima A.

Clin Chem Lab Med. 2007;45(9):1133-9.

PMID:
17635078
29.

Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage.

Billiet L, Furman C, Larigauderie G, Copin C, Page S, Fruchart JC, Brand K, Rouis M.

J Cell Physiol. 2008 Jan;214(1):183-91.

PMID:
17579352
30.

The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.

Brigadeau F, Gelé P, Wibaux M, Marquié C, Martin-Nizard F, Torpier G, Fruchart JC, Staels B, Duriez P, Lacroix D.

J Cardiovasc Pharmacol. 2007 Jun;49(6):408-15.

PMID:
17577106
31.

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.

Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4689-93. Epub 2007 May 24.

PMID:
17553678
32.

Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages.

Fontaine C, Rigamonti E, Nohara A, Gervois P, Teissier E, Fruchart JC, Staels B, Chinetti-Gbaguidi G.

Circ Res. 2007 Jul 6;101(1):40-9. Epub 2007 May 31.

PMID:
17540978
33.

PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis.

Quéméneur T, Martin-Nizard F, Kandoussi A, Kyndt X, Vanhille P, Hachulla E, Hatron PY, Fruchart JC, Duriez P, Lambert M.

Semin Arthritis Rheum. 2007 Dec;37(3):149-55. Epub 2007 May 21.

PMID:
17512573
34.

The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity.

Kahri J, Fruchart-Najib J, Matikainen N, Fruchart JC, Vakkilainen J, Taskinen MR.

Diabetes Care. 2007 Aug;30(8):2083-5. Epub 2007 May 7. No abstract available.

PMID:
17485571
36.

Safety issues and prospects for future generations of PPAR modulators.

Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B.

Biochim Biophys Acta. 2007 Aug;1771(8):1065-81. Epub 2007 Feb 24. Review.

PMID:
17428730
37.

Is lipoprotein(a) a clinically meaningful risk marker for cardiovascular events in healthy women?

Fruchart JC.

Nat Clin Pract Cardiovasc Med. 2007 May;4(5):242-3. Epub 2007 Mar 13. No abstract available.

PMID:
17356519
38.

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.

Gervois P, Fruchart JC, Staels B.

Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):145-56. Review.

PMID:
17237841
39.

[4-(2H-1,2,3-benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs).

Sparatore A, Godio C, Perrino E, Romeo S, Staels B, Fruchart JC, Crestani M.

Chem Biodivers. 2006 Apr;3(4):385-95.

PMID:
17193275
40.

Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.

Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM.

J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. Epub 2006 Oct 17.

41.

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1341-6. Review.

PMID:
17073815
42.

Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR.

Chinetti G, Fruchart JC, Staels B.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1128-31. Review. Erratum in: Biochem Soc Trans. 2007 Feb;35(Pt 1):165.

PMID:
17073767
43.

The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.

Lalloyer F, Fiévet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A.

Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28.

PMID:
17008586
44.

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.

Fiévet C, Fruchart JC, Staels B.

Curr Opin Pharmacol. 2006 Dec;6(6):606-14. Epub 2006 Sep 14. Review.

PMID:
16973418
45.

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.

Lancet. 2006 Sep 9;368(9539):919-28.

PMID:
16962881
46.

Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo.

Singaraja RR, Van Eck M, Bissada N, Zimetti F, Collins HL, Hildebrand RB, Hayden A, Brunham LR, Kang MH, Fruchart JC, Van Berkel TJ, Parks JS, Staels B, Rothblat GH, Fiévet C, Hayden MR.

Circulation. 2006 Sep 19;114(12):1301-9. Epub 2006 Aug 28.

PMID:
16940190
47.

Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.

Pourcet B, Fruchart JC, Staels B, Glineur C.

Expert Opin Emerg Drugs. 2006 Sep;11(3):379-401. Review.

PMID:
16939380
48.

Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development.

Cuaz-Pérolin C, Jguirim I, Larigauderie G, Jlassi A, Furman C, Moreau M, Chapman MJ, Fruchart JC, Slimane MN, Mezdour H, Rouis M.

J Vasc Res. 2006;43(6):493-501. Epub 2006 Aug 24.

PMID:
16931892
49.

Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of beta-oxidation.

Larigauderie G, Cuaz-Pérolin C, Younes AB, Furman C, Lasselin C, Copin C, Jaye M, Fruchart JC, Rouis M.

FEBS J. 2006 Aug;273(15):3498-510.

50.

Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells.

Helleboid-Chapman A, Helleboid S, Jakel H, Timmerman C, Sergheraert C, Pattou F, Fruchart-Najib J, Fruchart JC.

Cell Res. 2006 Jul;16(7):661-70.

Supplemental Content

Loading ...
Support Center